|Bid||8.18 x 800|
|Ask||8.20 x 900|
|Day's Range||8.11 - 8.56|
|52 Week Range||1.82 - 13.49|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2020. To access the conference call, investors are invited to dial 877-407-9716 (U.S. and Canada) or 201-493-6779 (international). The conference ID number is 13707645. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. For more information, please visit www.avadel.com.Contacts: Investor Contacts Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: email@example.com Tim McCarthy LifeSci Advisors, LLC Phone: (212) 915.2564 Email: firstname.lastname@example.org Media Contact Patrick Bursey LifeSci Communications, LLC Phone: (646) 970-4688 Email: email@example.com
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™, which is approved by the U.S. Food and Drug Administration, to Exela Sterile Medicines LLC for a total of $42.0 million. “The sale of the sterile injectable drug portfolio is a significant milestone for the Company, as it further reflects our commitment to strategically focus on advancing FT218 through the regulatory review process and, if approved, bringing our once-nightly formulation of sodium oxybate to patients,” said Greg Divis, Chief Executive Officer of Avadel.
DUBLIN, Ireland, June 08, 2020 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium.